|
|
Blood, 1 March 2004, Vol. 103, No. 5, pp. 1869-1875.
Prepublished online as a Blood First Edition Paper on October 30, 2003; DOI 10.1182/blood-2003-05-1465.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation
Manuel Montesinos-Rongen,
Dirk Van Roost,
Carlo Schaller,
Otmar D. Wiestler, and
Martina Deckert
From the Department of Neuropathology, University of Cologne, and the Departments of Neuropathology and Neurosurgery, University of Bonn, Germany.
We have addressed whether aberrant ongoing hypermutation can be detected in the proto-oncogenes PIM1, c-MYC, RhoH/TTF, PAX5, and the tumor-suppressor gene CD95 in primary central nervous system lymphomas (PCNSLs) derived from immunocompetent HIV-negative patients. Nine of 10 PCNSLs analyzed harbored somatic mutations in the PIM1, c-MYC, RhoH/TTF, and PAX5 genes, but not in the CD95 gene, with 8 tumors carrying alterations in at least 2 of these genes. Furthermore, ongoing aberrant mutation was evidenced in a subset of PCNSLs (2 of 3). Although most of the mutations corresponded to base pair substitutions, deletions were also present. The mean mutation frequency was approximately 60-fold lower for these genes compared with the values obtained for immunoglobulin genes in PCNSL. They were increased 2- to 5-fold compared with extracerebral diffuse large B-cell lymphoma (DLBCL). In summary, our data demonstrate aberrant somatic hypermutations at high frequency in the PIM1, PAX5, RhoH/TTF, and c-MYC genes in most PCNSLs. These findings may indicate a pathogenic role for aberrant somatic hypermutation in PCNSL development. In contrast, although mutations were detected in exon 9 of the CD95 gene, the lack of mutations in the 5' region provides no evidence for the CD95 gene as a target for aberrant somatic mutation.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. J. McCann, M. Ashton-Key, K. Smith, F. K. Stevenson, and C. H. Ottensmeier
Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development
Blood,
May 7, 2009;
113(19):
4677 - 4680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan
Primary CNS Lymphoma in Immunocompetent Patients
Oncologist,
May 1, 2009;
14(5):
526 - 539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kadoch, E. B. Dinca, R. Voicu, L. Chen, D. Nguyen, S. Parikh, J. Karrim, M. A. Shuman, C. A. Lowell, P. A. Treseler, et al.
Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model
Clin. Cancer Res.,
March 15, 2009;
15(6):
1989 - 1997.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Schlegel
Review: Primary CNS lymphoma
Therapeutic Advances in Neurological Disorders,
March 1, 2009;
2(2):
93 - 104.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Montesinos-Rongen, R. Siebert, and M. Deckert
Primary lymphoma of the central nervous system: just DLBCL or not?
Blood,
January 1, 2009;
113(1):
7 - 10.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Adamia, A. A. Reichert, H. Kuppusamy, J. Kriangkum, A. Ghosh, J. J. Hodges, P. M. Pilarski, S. P. Treon, M. J. Mant, T. Reiman, et al.
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia
Blood,
December 15, 2008;
112(13):
5111 - 5121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Balasenthil, A. E. Gururaj, A. H. Talukder, R. Bagheri-Yarmand, T. Arrington, B. J. Haas, J. C. Braisted, I. Kim, N. H. Lee, and R. Kumar
Identification of Pax5 as a Target of MTA1 in B-Cell Lymphomas
Cancer Res.,
August 1, 2007;
67(15):
7132 - 7138.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. A. Deutsch, A. Aigelsreiter, P. B. Staber, A. Beham, W. Linkesch, C. Guelly, R. I. Brezinschek, M. Fruhwirth, W. Emberger, M. Buettner, et al.
MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation
Blood,
April 15, 2007;
109(8):
3500 - 3504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Duquette, M. D. Huber, and N. Maizels
G-Rich Proto-Oncogenes Are Targeted for Genomic Instability in B-Cell Lymphomas
Cancer Res.,
March 15, 2007;
67(6):
2586 - 2594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Liso, D. Capello, T. Marafioti, E. Tiacci, M. Cerri, V. Distler, M. Paulli, A. Carbone, G. Delsol, E. Campo, et al.
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma
Blood,
August 1, 2006;
108(3):
1013 - 1020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Takahashi, F. Feuerhake, J. L. Kutok, S. Monti, P. Dal Cin, D. Neuberg, J. C. Aster, and M. A. Shipp
FAS Death Domain Deletions and Cellular FADD-like Interleukin 1{beta} Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3265 - 3271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Camilleri-Broet, E. Criniere, P. Broet, V. Delwail, K. Mokhtari, A. Moreau, M. Kujas, M. Raphael, W. Iraqi, C. Sautes-Fridman, et al.
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
Blood,
January 1, 2006;
107(1):
190 - 196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Montesinos-Rongen, R. Schmitz, C. Courts, W. Stenzel, D. Bechtel, G. Niedobitek, I. Blumcke, G. Reifenberger, A. von Deimling, B. Jungnickel, et al.
Absence of Immunoglobulin Class Switch in Primary Lymphomas of the Central Nervous System
Am. J. Pathol.,
June 1, 2005;
166(6):
1773 - 1779.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Pasqualucci, R. Guglielmino, J. Houldsworth, J. Mohr, S. Aoufouchi, R. Polakiewicz, R. S. K. Chaganti, and R. Dalla-Favera
Expression of the AID protein in normal and neoplastic B cells
Blood,
November 15, 2004;
104(10):
3318 - 3325.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|